Drug intelligence / Profile preview

NC101

Development stage: Preclinical
Lead developer: Innovate Biopharmaceuticals
Modality: Small Molecules
Administration: Retrograde Instillation Via Ureteral Catheter, Antegrade Instillation Via Nephrostomy Tube

Overview

NC101 is a repurposed drug under development by Naia Limited for the treatment of metabolic disorders, including type 2 diabetes mellitus and non-alcoholic steatohepatitis. It acts as an agonist at both the glucagon-like peptide-1 receptor (GLP-1R) and glucagon-like peptide-2 receptor (GLP-2R), making it part of the antihyperglycaemic class. As of the latest available information, it is not a new molecular entity and has not received orphan drug status. The highest reported development phase was preclinical in the United States for both type 2 diabetes mellitus and non-alcoholic steatohepatitis[1].

Other names: NC 101NC101NC-101

Targets

GLP1R (GLP-1R)GLP2R (Glucagon-like peptide 2 receptor)

Beyond the preview

Go deeper on NC101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NC101.

Explore the full profile